Nasdaq

Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate

cGMP production of 186RNL targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future ReSPECT™ clinical trials The FDA indicated agreement with the Company’s proposed ...
Business Wire

Medical Devices Post Market Surveillance and Complaint Handling Systems Course: U.S. FDA CGMP Expectations/Requirements (ONLINE EVENT/ON-DEMAND) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Medical Devices: Developing Effective Post Market Surveillance and Complaint Handling Systems Course" training has been added to ResearchAndMarkets.com's offering. This ...
CNBCTV18

US FDA flags 11 procedural observations at Eugia Pharma’s Telangana unit

The US Food and Drug Administration (US FDA) has completed a current good manufacturing practice (CGMP) inspection at ...
Business Wire

Virtual Course: Developing Effective Medical Devices Post Market Surveillance and Complaint Handling Systems Under Section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C ...

DUBLIN--(BUSINESS WIRE)--The "Medical Devices: Developing Effective Post Market Surveillance and Complaint Handling Systems" training has been added to ...
Morningstar

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's ...
Morningstar

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform Esco Aster, a vertically integrated ...